Shigeki Nanjo

Profile Information

Affiliation: Assistant Professor, Division of Medical Oncology, Cancer Research Institute, Kanazawa University

Researcher number: 00722555
ORCID ID: https://orcid.org/0000-0001-8356-9849
J-GLOBAL ID: 202001001994928328
researchmap Member ID: R000009744

Research Interests

Research Areas

Life sciences / Tumor biology / 肺癌、遺伝子変異、転移、薬物耐性

Research History

Dec, 2016 - Present

腫瘍内科, 金沢大学がん進展制御研究所
Dec, 2016 - Jul, 2021

腫瘍内科, カリフォルニア大学サンフランシスコ校
Dec, 2015 - Nov, 2016

総合腫瘍科, 先端医療センター
Apr, 2011 - Dec, 2015

腫瘍内科, 金沢大学がん進展制御研究所
Apr, 2008 - Mar, 2011

呼吸器内科, 神戸市立医療センター中央市民病院
Apr, 2007 - Mar, 2008

呼吸器内科, 大阪市立総合医療センター

Education

Apr, 2011 - Mar, 2014

Kanazawa University
Apr, 1999 - Mar, 2005

Osaka City University

Awards

Papers

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.

Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M Ali, D Lucas Kerr, Victor R Olivas, Jonathan Shue …

The Journal of clinical investigation, 132(13), Jul 1, 2022
Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases.

Koushiro Ohtsubo, Kunio Miyake, Sachiko Arai, Koji Fukuda, Chiaki Suzuki, Hiroshi Kotani, Azusa Tanimoto, Akihiro Nishiyama, Shigeki Nanjo, Kaname Yamashita …

Cancer diagnosis & prognosis, 2(3) 378-383, 2022
Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study).

Kouji Izumi, Hiroaki Iwamoto, Hiroshi Yaegashi, Takahiro Nohara, Kazuyoshi Shigehara, Yoshifumi Kadono, Shigeki Nanjo, Tadaaki Yamada, Koshiro Ohtsubo, Seiji Yano …

Journal of cachexia, sarcopenia and muscle, 12(4) 831-842, Aug, 2021
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.

Koji Fukuda, Sakiko Otani, Shinji Takeuchi, Sachiko Arai, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Katsuhiko Naoki, Seiji Yano

Cancer science, 112(9) 3784-3795, Jun 19, 2021
Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.

Jeffrey J Quinn, Matthew G Jones, Ross A Okimoto, Shigeki Nanjo, Michelle M Chan, Nir Yosef, Trever G Bivona, Jonathan S Weissman

Science (New York, N.Y.), 371(6532), Feb 26, 2021
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.

Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo …

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(5) 752-765, May, 2020 Peer-reviewed
CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

Ross A Okimoto, Wei Wu, Shigeki Nanjo, Victor Olivas, Yone K Lin, Rovingaile Kriska Ponce, Rieko Oyama, Tadashi Kondo, Trever G Bivona

The Journal of clinical investigation, 129(8) 3401-3406, Jul 22, 2019 Peer-reviewed
Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid.

Kei Irie, Shigeki Nanjo, Akito Hata, Yuta Yamasaki, Yutaka Okada, Nobuyuki Katakami, Shoji Fukushima

Bioanalysis, 11(9) 847-854, May, 2019 Peer-reviewed
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.

Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki …

Cancer research, 79(7) 1658-1670, Apr 1, 2019 Peer-reviewed
Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

Shigeki Nanjo, Trever G Bivona

Journal of thoracic disease, 10(Suppl 33) S4061-S4064, Nov, 2018 Peer-reviewed
Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer.

Kei Irie, Saori Shobu, Seika Hiratsuji, Yuta Yamasaki, Shigeki Nanjo, Chiyuki Kokan, Akito Hata, Reiko Kaji, Katsuhiro Masago, Shiro Fujita …

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1087-1088 1-5, Jun 15, 2018 Peer-reviewed
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Shigeki Nanjo, Akito Hata, Chiyuki Okuda, Reiko Kaji, Hideaki Okada, Daisuke Tamura, Kei Irie, Hiroshi Okada, Shoji Fukushima, Nobuyuki Katakami

British journal of cancer, 118(1) 32-37, Jan, 2018 Peer-reviewed
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.

Akito Hata, Nobuyuki Katakami, Shigeki Nanjo, Chiyuki Okuda, Reiko Kaji, Katsuhiro Masago, Shiro Fujita, Hiroshi Yoshida, Kota Zama, Yukihiro Imai …

Oncotarget, 8(69) 113807-113816, Dec 26, 2017 Peer-reviewed
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.

Akito Hata, Nobuyuki Katakami, Shigeki Nanjo, Chiyuki Okuda, Reiko Kaji, Katsuhiro Masago, Shiro Fujita, Hiroshi Yoshida, Kota Zama, Yukihiro Imai …

Lung cancer (Amsterdam, Netherlands), 111 182-189, Sep, 2017 Peer-reviewed
MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.

Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano

Molecular cancer therapeutics, 16(3) 506-515, Mar, 2017 Peer-reviewed
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.

Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Takayuki Nakagawa, Sachiko Arai, Shigeki Nanjo, Tadaaki Yamada, Hiroyuki Yamaguchi, Hiroshi Mukae, Seiji Yano

Cancer science, 108(1) 53-60, Jan, 2017 Peer-reviewed
Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study).

Kouji Izumi, Kazuyoshi Shigehara, Takahiro Nohara, Kazutaka Narimoto, Yoshifumi Kadono, Shigeki Nanjo, Tadaaki Yamada, Koushiro Ohtsubo, Seiji Yano, Atsushi Mizokami

The journal of medical investigation : JMI, 64(3.4) 202-204, 2017 Peer-reviewed
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression

H. Kotani, H. Ebi, H. Kitai, S. Nanjo, K. Kita, T. G. Huynh, A. Ooi, A. C. Faber, M. Mino-Kenudson, S. Yano

ONCOGENE, 35(27) 3587-3597, Jul, 2016 Peer-reviewed
Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration.

Azusa Tanimoto, Shinji Takeuchi, Hiroshi Yaegashi, Hiroshi Kotani, Hidenori Kitai, Shigeki Nanjo, Hiromichi Ebi, Kaname Yamashita, Hisatsugu Mouri, Koushiro Ohtsubo …

Molecular and clinical oncology, 4(4) 537-540, Apr, 2016 Peer-reviewed
Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.

Shinji Takeuchi, Koji Fukuda, Sachiko Arai, Shigeki Nanjo, Kenji Kita, Tadaaki Yamada, Eiji Hara, Hiroshi Nishihara, Hisanori Uehara, Seiji Yano

International journal of cancer, 138(5) 1281-9, Mar 1, 2016 Peer-reviewed

Misc.

160

ALK転座陽性肺癌においてEMTは独立した耐性機構として関与する(Epithelial-to-mesenchymal transition as an independent mechanism of ALK inhibitor resistance in EML4-ALK lung cancer)

福田康二, 竹内伸司, 片山量平, 南條成輝, 谷本梓, 鈴木健之, 竹内賢吾, 西尾誠人, 矢野聖二

日本癌学会総会記事, 77回 186-186, Sep, 2018
AREGによるEML4-ALK肺癌のクリゾチニブ耐性とEGFR阻害薬による耐性克服

谷口寛和, 竹内伸司, 福田康二, 中川学之, 新井祥子, 南條成輝, 山田忠明, 山口博之, 迎寛, 矢野聖二

日本癌学会総会記事, 76回 P-2332, Sep, 2017
当院におけるオシメルチニブの使用経験

奥田千幸, 吉積悠子, 南條成輝, 秦明登, 加地玲子, 真砂勝泰, 藤田史郎, 片上信之

肺癌, 57(3) 235-236, Jun, 2017
気管支腔内照射後の瘢痕性収縮に対し気管支鏡下バルーン拡張術が有効であった一例

奥田千幸, 吉積悠子, 南條成輝, 秦明登, 加地玲子, 真砂勝泰, 藤田史郎, 片上信之

気管支学, 39(Suppl.) S387-S387, May, 2017
HDAC Inhibition Overcomes Crizotinib-Resistance by Mesenchymal-Epithelial Transition (MET) in EML4-ALK Lung Cancer Cells

Koji Fukuda, Shinji Takeuchi, Ryohei Katayama, Shigeki Nanjo, Tadaaki Yamada, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano

JOURNAL OF THORACIC ONCOLOGY, 12(1) S382-S383, Jan, 2017
MET Copy Number Gain Associates with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer

Seiji Yano, Shigeki Nanjo, Sachiko Arai, Shinji Takeuchi, Tadaaki Yamada, Yasunori Okada, Akito Hata, Nobuyuki Katakami

JOURNAL OF THORACIC ONCOLOGY, 12(1) S272-S273, Jan, 2017
アレクチニブによる治療後に小細胞癌への転化がみられたALK陽性肺癌の1例

奥田千幸, 藤田史郎, 南條成輝, 秦明登, 加地玲子, 真砂勝泰, 片上信之

肺癌, 56(7) 1065-1065, Dec, 2016
既治療非小細胞肺癌におけるT790M遺伝子/PD-L1発現確認目的の組織採取のための再生検

秦明登, 南條成輝, 奥田千幸, 加地玲子, 真砂勝泰, 藤田史郎, 片上信之

肺癌, 56(7) 1066-1066, Dec, 2016
癌性髄膜炎合併T790M陽性非小細胞肺癌に対するオシメルチニブのパイロットスタディ

秦明登, 南條成輝, 吉積悠子, 奥田千幸, 加地玲子, 真砂勝泰, 藤田史郎, 入江慶, 岡田裕, 岡田秀明 …

肺癌, 56(6) 509-509, Nov, 2016
ALK融合遺伝子陽性肺がんにおける上皮間葉転換によるCrizotinib耐性機構の解明と克服治療の開発

竹内伸司, 福田康二, 片山量平, 南條成輝, 山田忠明, 鈴木健之, 竹内賢吾, 西尾誠人, 矢野聖二

肺癌, 56(6) 552-552, Nov, 2016
非小細胞肺癌に対するシスプラチン+ペメトレキセド同時併用の化学放射線療法単一施設からの後ろ向き検討

秦明登, 吉積悠子, 奥田千幸, 南條成輝, 加地玲子, 真砂勝泰, 藤田史郎, 片上信之, 高山賢二, 今葷倍敏行

肺癌, 56(6) 651-651, Nov, 2016
ALK転座陽性肺癌においてEMTが惹起するALK阻害薬耐性に対するHDAC阻害薬の効果

福田康二, 竹内伸司, 片山量平, 南條成輝, 竹内賢吾, 西原広史, 西尾誠人, 矢野聖二

日本癌学会総会記事, 75回 J-3070, Oct, 2016
肺肺がんのバイオマーカー探求既治療非小細胞肺癌におけるT790M遺伝子/PD-L1発現確認目的の組織採取のための再生検

秦明登, 片上信之, 南條成輝, 奥田千幸, 加地玲子, 真砂勝泰, 藤田史郎

日本癌治療学会学術集会抄録集, 54回 MS45-2, Oct, 2016
EUSにおける主膵管拡張を契機とし、連続膵液細胞診(serial pancreatic juice aspiration cytological examination:SPACE)にて診断された膵上皮内癌の1切除例

大坪公士郎, 足立雄太, 谷口寛和, 谷本梓, 北井秀典, 小谷浩, 西山明宏, 南條成輝, 渡辺一孝, 竹内伸司 …

ENDOSCOPIC FORUM for digestive disease, 32(1) 67-67, May, 2016
シスプラチン+ペメトレキセド併用の同時化学放射線療法の経験

秦明登, 吉積悠子, 加藤了資, 奥田千幸, 南條成輝, 加地玲子, 真砂勝泰, 藤田史郎, 片上信之, 高山賢二

肺癌, 56(2) 137-137, Apr, 2016
肺癌基礎 EGFR変異肺癌の髄膜癌腫症モデルでの中枢神経系における新たな耐性機序の克服

南條成輝, 片上信之, 衣斐寛倫, 竹内伸二, 岡田保典, 矢野聖二

日本呼吸器学会誌, 5(増刊) 164-164, Mar, 2016
癌性腹膜炎に対するCART(腹水濾過濃縮再静注法)施行症例の検討

足立雄太, 西山明宏, 渡辺一孝, 南條成輝, 竹内伸司, 山田忠明, 衣斐寛倫, 毛利久継, 大坪公士郎, 矢野聖二

日本内科学会雑誌, 105(Suppl.) 232-232, Feb, 2016
当科で分子標的薬を導入した甲状腺癌症例の後方視的検討

西山明宏, 谷口寛和, 南條成輝, 渡辺一孝, 竹内伸司, 衣斐寛倫, 山田忠明, 毛利久継, 大坪公士郎, 矢野聖二

日本内科学会雑誌, 105(Suppl.) 272-272, Feb, 2016
膵管内乳頭粘液性腫瘍を合併した膵管癒合不全に対して副乳頭切開とパンクレリパーゼ投与にて症状緩和が得られた1例

大坪公士郎, 谷本梓, 足立雄太, 谷口寛和, 北井秀典, 小谷浩, 西山明宏, 渡辺一孝, 南條成輝, 竹内伸司 …

ENDOSCOPIC FORUM for digestive disease, 31(2) 187-187, Nov, 2015
分子標的薬耐性 EGFR変異肺癌の髄膜癌腫症モデルにおける新世代EGFR-TKI AZD9291の有用性

南條成輝, 片上信之, 竹内伸司, 衣斐寛倫, 望月早月, 岡田保典, 矢野聖二

肺癌, 55(5) 399-399, Oct, 2015

Research Projects

Study to form a theoretical basis for personalized medicine that stratifies EGFR-mutated lung cancer by co-mutations

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2023 - Mar, 2026
EGFR変異肺がんにおいて併存するRBM10遺伝子変異の機能解析

科学研究費助成事業若手研究, 若手研究, 日本学術振興会, Apr, 2021 - Mar, 2023

南條成輝
A multicenter, single arm phase Ⅱ study to examine efficacy and cerebrospinal fluid transitivity of Osimertinib in leptomeningeal carcinomatosis (LMC) patients with non-small cell lung cancer harboring EGFR mutation

Sep, 2016 - Mar, 2019

Profile Information

Research Interests

Research Areas

Research History

Education

Awards

Papers

Misc.

Research Projects

Menu

Coauthors